The trial will assess the safety, efficacy, pharmacokinetics and biological effects of KT-474 in moderate to severe hidradenitis suppurativa patients. Credit: Kristi Blokhin / Shutterstock.com.

Kymera Therapeutics has announced the dosing of the first subject in the Phase II clinical trial of KT-474 (SAR444656) to treat hidradenitis suppurativa (HS), a chronic inflammatory skin ailment.

The randomised trial will assess the safety, efficacy, pharmacokinetics and biological effects of KT-474 versus placebo in adults with moderate to severe HS. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under a partnership deal with Sanofi, Kymera received $40m in milestone payment following the initiation of subject dosing in the HS trial.

Currently, Sanofi is carrying out the Phase II study in HS and has also commenced a second randomised Phase II trial in atopic dermatitis (AD) patients.

The dosing of the first subject in the AD trial is anticipated later this quarter.

See Also:

Subsequent to the dosing in this AD trial, Kymera will also receive an additional milestone payment from Sanofi.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kymera Therapeutics founder, president and CEO Nello Mainolfi said: “The initiation of dosing in the first Phase II trial of KT-474 in HS is an important step in the development of this molecule and a significant achievement for Kymera in demonstrating the potential of protein degradation to transform the treatment of complex, inflammatory diseases with small molecules. 

“Based on the encouraging KT-474 Phase I results, we believe that this molecule has the potential to offer HS patients a well-tolerated and effective oral drug.”

An oral degrader of interleukin 1 receptor-associated kinase 4 (IRAK4), KT-474 is being developed to treat various complex inflammatory ailments.